{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-24-213132","form_type":"8-K","ticker":"INAB","cik":"0001740279","company_name":"IN8BIO, INC.","filed_at":"2024-09-04T23:59:59+00:00","discovered_at":"2026-05-14T18:03:14.375995+00:00","generated_at":"2026-05-31T06:28:08.565808+00:00","sec_items":["2.05","8.01","9.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"IN8bio cuts workforce 49%, suspends GBM trial to focus on AML therapy INB-100","bullets":["Workforce reduced from 37 to 19 FTEs; exec/board take 11% cash compensation cut.","One-time severance costs of ~$0.3M expected in Q3 2024.","INB-100 Phase 1 AML trial shows 100% relapse-free survival at median 18.7 months follow-up; expansion cohort targeting ~25 patients by H1 2025.","Enrollment suspended in INB-400 Phase 2 GBM trial; IN8bio will monitor existing patients and explore partnerships.","Company exploring other strategic alternatives to preserve cash."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-24-213132","json":"https://secwatch.observer/filing/0001193125-24-213132.json","markdown":"https://secwatch.observer/filing/0001193125-24-213132.md","text":"https://secwatch.observer/filing/0001193125-24-213132.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1740279/000119312524213132/0001193125-24-213132-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1740279/000119312524213132/d855704d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-31T06:28:08.565808+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"93e80edd6f88b3a709ebaa651b74addae2db6100","claim":"IN8BIO, INC. announced a restructuring with charges of approximately $0.3 million affecting all functional areas, New York City and Birmingham, Alabama sites (from 37 to 19 full-time employees).","evidence_excerpt":"such employee’s execution of a separation agreement, which includes a general release of claims against the Company. The Company expects to incur one-time costs of approximately $0.3 million in connection with this workforce reduction, of which nearly all are cash expenditures related to severance. The Company communicated the workforce reduction on September 4, 2024","evidence_source":"SEC 8-K Item 2.05/2.06","evidence_url":"https://www.sec.gov/Archives/edgar/data/1740279/000119312524213132/0001193125-24-213132-index.htm","confidence":0.95,"family_label":"Restructurings & Charges","details":[{"label":"Type","value":"restructuring"},{"label":"Charge","value":"approximately $0.3 million"},{"label":"Affected area","value":"all functional areas, New York City and Birmingham, Alabama sites"},{"label":"Headcount","value":"from 37 to 19 full-time employees"}],"fact_type":"restructuring_charge"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}